Robinson, S. (2025). First-in-class TMBIM6 therapeutics: Overcoming limitations in current oncology therapies through ERAD-II induced paraptosis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e15120